Study to Evaluate the Safety and Tolerability of Weekly Intravenous (IV) Doses of BMS-906024 in Subjects With Acute T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma

Minimum Age: 10 years and older at selected sites

For more information regarding BMS clinical trial participation, please visit
www.BMSStudyConnect.com.

Inclusion Criteria:

- Subjects with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma
refractory to or relapsed from standard therapies

- Life expectancy of at least 2 months

- Performance status (PS) 0-1 (a measure of the ability to carry out activities of daily
living); subjects with PS 2 are eligible if due to disease related symptoms

- Prior anti-cancer treatment permitted (with specific criteria)

- Adequate organ function

Exclusion Criteria:

- Infection

- Elevated triglycerides

- Gastro-intestinal disease with increased risk of diarrhea (e.g. inflammatory bowel
disease)

- Unable to tolerate bone marrow biopsy

- Taking medications known to increase risk of Torsades De Pointes (an abnormal heart
rhythm)